Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dutasteride

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Dutasteride. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-001802-23 Sponsor Protocol Number: ALOSTOP Start Date*: 2022-08-24
    Sponsor Name:Fundación para la Investigación Biomédica Hospital Ramón y Cajal
    Full Title: Exploratory clinical trial of safety and efficacy of daily application of topical dutasteride in emulsion in men with androgenic alopecia.
    Medical condition: Male androgenetic alopecia
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012405-18 Sponsor Protocol Number: 09/0221 Start Date*: 2010-02-15
    Sponsor Name:University College London
    Full Title: Single site, phase II, double blind, randomised, placebo controlled study of the effect of dutasteride (Avodart)0.5 mg on the volume and characteristics of prostate cancer, as assessed by multifunc...
    Medical condition: Low risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2006-003023-37 Sponsor Protocol Number: ARI106807 Start Date*: 2006-12-21
    Sponsor Name:GlaxoSmithKline UK
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase IV Study to Evaluate the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Daily for 24 Weeks to Reduce the Risk of Acut...
    Medical condition: Reduction of risk of acute urinary retention relapse
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046555 Urinary retention LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001703-38 Sponsor Protocol Number: ARI109924 Start Date*: 2007-09-25
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochem...
    Medical condition: Clinically localised prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) SE (Completed) FR (Completed) ES (Completed) LT (Prematurely Ended) LV (Prematurely Ended) NL (Completed) GB (Completed) EE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001989-38 Sponsor Protocol Number: IMCRELA Start Date*: 2021-07-08
    Sponsor Name:Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
    Full Title: IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004872-11 Sponsor Protocol Number: 169/2004/U/Sper Start Date*: 2005-01-28
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Role of testosterone and its metabolites on different physiological functions in subjects affected by gender identity disorde GID FtM transsexuals
    Medical condition: Maintenance of the characteristics and functions androgen-employee in FtM subjects after participation of RCS isteroannessiectomia.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10044337 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004321-15 Sponsor Protocol Number: H6D-MC-LVHK(b) Start Date*: 2007-12-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign P...
    Medical condition: Effects on urodynamic parameters in men with benign prostatic hyperplasia (also referred to as BPH-LUTS [lower urinary tract symptoms]) with and without urodynamic evidence of bladder outlet obstru...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003251-74 Sponsor Protocol Number: 62/2008/U/Sper Start Date*: 2008-06-24
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ROLE OF TESTOSTERONE AND ITS METABOLITE DIHYDROTESTOSTERONE ON METABOLISM AND ON MUSCLE STRENGTH IN SUBJECTS AFFECTED BY GENEDER IDENTITY DISORDER (GID) (FtM TRANSSEXUALS)
    Medical condition: GENDER IDENTITY DISORDER (GID) (FtM TRANSSEXUALS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061976 Gender identity disorder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004322-24 Sponsor Protocol Number: ARN-509-003 Start Date*: 2013-08-27
    Sponsor Name:Aragon Pharmaceuticals, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
    Medical condition: Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned) FI (Completed) SE (Completed) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NO (Completed) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) HU (Completed) CZ (Trial now transitioned) SK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010739-42 Sponsor Protocol Number: H6D-MC-LVID Start Date*: 2009-10-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) BE (Completed) AT (Completed) IT (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020604-29 Sponsor Protocol Number: H6D-CR-LVIW(a), Addendum 1 u.4 Start Date*: 2010-11-05
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 3b,randomized,double-blind,placebo-controlled parallel-design study to evaluate the efficacy and safety of tadalafil coadministered with finasteride for 6 months in men with lower urinary ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020220-22 Sponsor Protocol Number: H6D-MC-LVIR Start Date*: 2010-12-21
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men with Signs and Symptoms of Be...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022111-19 Sponsor Protocol Number: FDC114615 Start Date*: 2010-11-22
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: Study FDC114615: Comparative efficacy of DuodartTM plus lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naïve men wi...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) FR (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002047-26 Sponsor Protocol Number: FDC116115 Start Date*: 2012-10-03
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: FDC116115: A prospective study of sexual function in sexually active men treated for BPH
    Medical condition: BPH (Benign prostatic hyperplasia)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    15.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed) NL (Completed) HU (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001958-27 Sponsor Protocol Number: H6D-MC-LVHG Start Date*: 2006-07-13
    Sponsor Name:Lilly ICOS LLC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men ...
    Medical condition: Primary treatment of the signs and symptoms of benign prostatic hyperplasia in men (also referred to as BPH-LUTS [lower urinary tract symptoms]). BPH-LUTS include urinary frequency, urgency, interm...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016800-22 Sponsor Protocol Number: I1A-MC-BPAE Start Date*: 2010-05-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (B...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003542-21 Sponsor Protocol Number: ALADDIN Start Date*: 2022-02-28
    Sponsor Name:ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie
    Full Title: Evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases
    Medical condition: Prostate cancer with pelvic lymph nodes metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002841-21 Sponsor Protocol Number: H6D-MC-LVHJ(a) Start Date*: 2008-10-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of B...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022255-37 Sponsor Protocol Number: CHUBX2010/39 Start Date*: 2010-09-29
    Sponsor Name:CHU de Bordeaux
    Full Title: Etude de l’efficacité et de la tolérance, de l’injection intra prostatique de toxine botulique A, chez l’homme, dans le traitement de l’hyperplasie bénigne de prostate symptomatique.
    Medical condition: HBP symptomatique modérée à sévère selon le score IPSS
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020728 Hyperplasia of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001128-31 Sponsor Protocol Number: 13-23 Start Date*: 2014-09-23
    Sponsor Name:Cancer Trials Ireland
    Full Title: Phase II Single-arm Study evaluating Neo-adjuvant (pre-radical radiotherapy) Abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist in high risk localised prostat...
    Medical condition: High-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 10:19:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA